ARVEE · Arvee Laboratories (India) Ltd · Chemical Manufacturing
ARVEE · Arvee Laboratories (India) Ltd · Chemical Manufacturing
As of 05 Nov close
52-week range
25.5% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹17 Cr
Revenue YoY
PAT YoY
+894.1%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
5.5
P/S (TTM)
4.8
Sector P/E
20.6
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| ARVEE (this stock) | 45 | 5.5 | +9.8% | +12.0% | 0.03 | 0.0% |
| Asian Paints | 53 | 11.1 | +12.8% | +22.3% | 0.18 | +1.1% |
| Pidilite Industries | 61.3 | 19.4 | +17.2% | +24.4% | 0.04 | +0.7% |
| Solar Industries India | 102.6 | 27.4 | +17.6% | +31.4% | 13.68 | +0.1% |
Promoter
stable
FII
Not available from data source
MF
Not available from data source
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 24 Sept 2026 | Saurin Ajitbhai Gandhi | SELL | 3,010 | ₹6.64 lakh |
| 23 Sept 2026 | Saurin Ajitbhai Gandhi | SELL | 990 | ₹2.5 lakh |
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedArvee Laboratories (India) Limited's annual report for FY2025-26 outlines the company's compliance with regulatory requirements, including the submission of financial statements and the Board's report. The report highlights a decrease in total revenue by 17.74% compared to the previous year, while management reports that net profit after tax increased by approximately 17.65%. The company emphasizes its commitment to corporate governance, internal financial controls, and adherence to legal and regulatory standards. The report also mentions the reappointment of directors and the absence of significant legal or regulatory issues affecting the company's operations.
- The company reported a decrease in total revenue by 17.74% for FY2025-26 compared to the previous year.
- Management reports that net profit after tax increased by approximately 17.65% despite the revenue decline.
- The company emphasizes strong corporate governance practices, including internal financial controls and compliance with legal and regulatory standards.
- The report mentions the reappointment of directors, including independent directors, and the absence of significant legal or regulatory issues affecting operations.
Key takeaway: Despite a notable decrease in revenue, Arvee Laboratories (India) Limited reported an increase in net profit after tax, highlighting the company's focus on cost management and operational efficiency.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (3 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
3 occurrencesEarlier (1-3 years ago)
The company was fined Rs. 4720/- by the exchange for delaying the submission of the annual report by 2 days in 2022-2023 under Regulation 34 of SEBI Listing Regulations 2015.
The company delayed submission of annual report to the exchange by 2 days, leading to a fine of Rs. 4720/- imposed by the exchange under Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations.
Older (3+ years ago)
The company delayed submission of annual report to the exchange by 2 days, leading to a fine of Rs. 4720/- imposed by the exchange under Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
Routine disclosures
Contingent Liability
2 occurrencesEarlier (1-3 years ago)
The company has contingent liabilities, but the specific amounts or details are not provided in the excerpt.
Older (3+ years ago)
The company has contingent liabilities and commitments, but the specific amounts or details are not provided in the excerpt.
Related-Party Transaction
2 occurrencesEarlier (1-3 years ago)
The company has transactions with related parties including directors and their family members, involving payments such as salary, loans, interest, rent, and professional fees. These transactions include amounts like 5,000.00 and 9,742.67 in thousands.
Older (3+ years ago)
The company has related party transactions with Arvee Specialty Chemicals Private Limited, involving sale, purchase, or supply of goods or services, with an aggregate value not exceeding 50 crore rupees per year. The transactions are proposed to be approved via an ordinary resolution under Section 188 of the Companies Act, 2013.